Literature DB >> 24672036

Cryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine development.

Minqing Gong1, Hongtao Zhu, Jun Zhou, Chunting Yang, Jing Feng, Xiaojun Huang, Gang Ji, Honglin Xu, Ping Zhu.   

Abstract

UNLABELLED: Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) are the two most common etiological agents responsible for the epidemics of hand, foot, and mouth disease (HFMD), a childhood illness with occasional severe neurological complications. A number of vaccine candidates against EV71 or CA16 have been reported; however, no vaccine is currently available for clinical use. Here, we generated a secreted version of EV71 and CA16 virus-like particles (VLPs) using a baculovirus-insect cell expression system and reconstructed the three-dimensional (3D) structures of both VLPs by cryo-electron microscopy (cryo-EM) single-particle analysis at 5.2-Å and 5.5-Å resolutions, respectively. The reconstruction results showed that the cryo-EM structures of EV71 and CA16 VLPs highly resemble the recently published crystal structures for EV71 natural empty particles and CA16 135S-like expanded particles, respectively. Our cryo-EM analysis also revealed that the majority of previously identified linear neutralizing epitopes are well preserved on the surface of EV71 and CA16 VLPs. In addition, both VLPs were able to induce efficiently neutralizing antibodies against various strains of EV71 and CA16 viruses in mouse immunization. These studies provide a structural basis for the development of insect cell-expressed VLP vaccines and for a potential bivalent VLP vaccine against both EV71- and CA16-associated HFMD. IMPORTANCE: The recent outbreaks of hand, foot, and mouth disease (HFMD) in the Asia Pacific region spurred the search for effective vaccines against EV71 and CA16 viruses, the two most common etiological agents responsible for HFMD. In this paper, we show that secreted versions of EV71 and CA16 VLPs generated in the baculovirus-insect cell expression system highly resemble the crystal structures of their viral conterparts and that the majority of previously identified linear neutralizing epitopes are well preserved on the VLP surfaces. In addition, the generated VLPs can efficiently induce neutralizing antibodies against various strains of EV71 and CA16 viruses in mouse immunization. These studies provide a structural basis for the development of insect cell-expressed VLP vaccines and for a potential bivalent VLP vaccine against both EV71- and CA16-associated HFMD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24672036      PMCID: PMC4093858          DOI: 10.1128/JVI.00200-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months.

Authors:  Yue-Mei Hu; Xu Wang; Jun-Zhi Wang; Ling Wang; Yong-Jie Zhang; Lin Chang; Zheng-Lun Liang; Jie-Lai Xia; Qi-Gang Dai; Ya-Ling Hu; Qun-Ying Mao; Feng-Cai Zhu; Yu-Fei Song; Fan Gao; Jiang-Ting Chen
Journal:  Clin Vaccine Immunol       Date:  2013-10-09

2.  Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16.

Authors:  Jinping Shi; Xulin Huang; Qingwei Liu; Zhong Huang
Journal:  Vaccine       Date:  2013-03-13       Impact factor: 3.641

3.  Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection.

Authors:  Yicun Cai; Qingwei Liu; Xulin Huang; Dapeng Li; Zhiqiang Ku; Yunfang Zhang; Zhong Huang
Journal:  Vaccine       Date:  2013-03-13       Impact factor: 3.641

4.  Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial.

Authors:  Feng-Cai Zhu; Zheng-Lun Liang; Xiu-Ling Li; Heng-Ming Ge; Fan-Yue Meng; Qun-Ying Mao; Yun-Tao Zhang; Yue-Mei Hu; Zhen-Yu Zhang; Jing-Xin Li; Fan Gao; Qing-Hua Chen; Qi-Yan Zhu; Kai Chu; Xing Wu; Xin Yao; Hui-Jie Guo; Xiao-Qin Chen; Pei Liu; Yu-Ying Dong; Feng-Xiang Li; Xin-Liang Shen; Jun-Zhi Wang
Journal:  Lancet       Date:  2013-03-23       Impact factor: 79.321

5.  Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Feng-Cai Zhu; Fan-Yue Meng; Jing-Xin Li; Xiu-Ling Li; Qun-Ying Mao; Hong Tao; Yun-Tao Zhang; Xin Yao; Kai Chu; Qing-Hua Chen; Yue-Mei Hu; Xing Wu; Pei Liu; Lin-Yang Zhu; Fan Gao; Hui Jin; Yi-Juan Chen; Yu-Ying Dong; Yong-Chun Liang; Nian-Min Shi; Heng-Ming Ge; Lin Liu; Sheng-Gen Chen; Xing Ai; Zhen-Yu Zhang; Yu-Guo Ji; Feng-Ji Luo; Xiao-Qin Chen; Ya Zhang; Li-Wen Zhu; Zheng-Lun Liang; Xin-Liang Shen
Journal:  Lancet       Date:  2013-05-29       Impact factor: 79.321

6.  Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice.

Authors:  Hao-Yang Li; Jian-Feng Han; Cheng-Feng Qin; Rong Chen
Journal:  Vaccine       Date:  2013-05-29       Impact factor: 3.641

7.  Structures of the procapsid and mature virion of enterovirus 71 strain 1095.

Authors:  Javier O Cifuente; Hyunwook Lee; Joshua D Yoder; Kristin L Shingler; Michael S Carnegie; Jennifer L Yoder; Robert E Ashley; Alexander M Makhov; James F Conway; Susan Hafenstein
Journal:  J Virol       Date:  2013-05-01       Impact factor: 5.103

8.  Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice.

Authors:  Hui Zhao; Hao-Yang Li; Jian-Feng Han; Yong-Qiang Deng; Yue-Xiang Li; Shun-Ya Zhu; Ya-Ling He; E-De Qin; Rong Chen; Cheng-Feng Qin
Journal:  Appl Microbiol Biotechnol       Date:  2013-10-02       Impact factor: 4.813

9.  Picornavirus uncoating intermediate captured in atomic detail.

Authors:  Jingshan Ren; Xiangxi Wang; Zhongyu Hu; Qiang Gao; Yao Sun; Xuemei Li; Claudine Porta; Thomas S Walter; Robert J Gilbert; Yuguang Zhao; Danny Axford; Mark Williams; Katherine McAuley; David J Rowlands; Weidong Yin; Junzhi Wang; David I Stuart; Zihe Rao; Elizabeth E Fry
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children.

Authors:  Qunying Mao; Tong Cheng; Fengcai Zhu; Jingxin Li; Yiping Wang; Yanping Li; Fan Gao; Lisheng Yang; Xin Yao; Jie Shao; Ningshao Xia; Zhenglun Liang; Junzhi Wang
Journal:  PLoS One       Date:  2013-11-19       Impact factor: 3.240

View more
  16 in total

1.  Crystal Structures of Yeast-Produced Enterovirus 71 and Enterovirus 71/Coxsackievirus A16 Chimeric Virus-Like Particles Provide the Structural Basis for Novel Vaccine Design against Hand-Foot-and-Mouth Disease.

Authors:  Ke Lyu; Ya-Ling He; Hao-Yang Li; Rong Chen
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

2.  Beta-Propiolactone Inactivation of Coxsackievirus A16 Induces Structural Alteration and Surface Modification of Viral Capsids.

Authors:  Chen Fan; Xiaohua Ye; Zhiqiang Ku; Liangliang Kong; Qingwei Liu; Cong Xu; Yao Cong; Zhong Huang
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

3.  Structure, Immunogenicity, and Protective Mechanism of an Engineered Enterovirus 71-Like Particle Vaccine Mimicking 80S Empty Capsid.

Authors:  Xiaoli Wang; Zhiqiang Ku; Xiang Zhang; Xiaohua Ye; Jinhuan Chen; Qingwei Liu; Wei Zhang; Chao Zhang; Zhenglin Fu; Xia Jin; Yao Cong; Zhong Huang
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103

4.  The enterovirus 71 procapsid binds neutralizing antibodies and rescues virus infection in vitro.

Authors:  Kristin L Shingler; Javier O Cifuente; Robert E Ashley; Alexander M Makhov; James F Conway; Susan Hafenstein
Journal:  J Virol       Date:  2014-11-26       Impact factor: 5.103

5.  Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice.

Authors:  Hui Zhao; Hao-Yang Li; Jian-Feng Han; Yong-Qiang Deng; Shun-Ya Zhu; Xiao-Feng Li; Hui-Qin Yang; Yue-Xiang Li; Yu Zhang; E-De Qin; Rong Chen; Cheng-Feng Qin
Journal:  Sci Rep       Date:  2015-01-19       Impact factor: 4.379

Review 6.  EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases.

Authors:  Qunying Mao; Yiping Wang; Lianlian Bian; Miao Xu; Zhenglun Liang
Journal:  Emerg Microbes Infect       Date:  2016-07-20       Impact factor: 7.163

7.  A Broadly Cross-protective Vaccine Presenting the Neighboring Epitopes within the VP1 GH Loop and VP2 EF Loop of Enterovirus 71.

Authors:  Longfa Xu; Delei He; Lisheng Yang; Zhiqun Li; Xiangzhong Ye; Hai Yu; Huan Zhao; Shuxuan Li; Lunzhi Yuan; Hongliu Qian; Yuqiong Que; James Wai Kuo Shih; Hua Zhu; Yimin Li; Tong Cheng; Ningshao Xia
Journal:  Sci Rep       Date:  2015-08-05       Impact factor: 4.379

8.  Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice.

Authors:  Elizabeth A Caine; Jeremy Fuchs; Subash C Das; Charalambos D Partidos; Jorge E Osorio
Journal:  Viruses       Date:  2015-11-17       Impact factor: 5.048

9.  Coxsackievirus A16 induced neurological disorders in young gerbils which could serve as a new animal model for vaccine evaluation.

Authors:  Yi-Sheng Sun; Ya-Jing Li; Yong Xia; Fang Xu; Wei-Wei Wang; Zhang-Nv Yang; Hang-Jing Lu; Zhi-Ping Chen; Zi-Ping Miao; Wei-Feng Liang; Zhi-Yao Xu; Hong-Jun Dong; Dan-Hong Qiu; Zhi-Yong Zhu; Stijn van der Veen; Jie Qian; Bin Zhou; Ping-Ping Yao; Han-Ping Zhu
Journal:  Sci Rep       Date:  2016-09-26       Impact factor: 4.379

10.  Structures of Coxsackievirus A16 Capsids with Native Antigenicity: Implications for Particle Expansion, Receptor Binding, and Immunogenicity.

Authors:  Jingshan Ren; Xiangxi Wang; Ling Zhu; Zhongyu Hu; Qiang Gao; Pan Yang; Xuemei Li; Junzhi Wang; Xinliang Shen; Elizabeth E Fry; Zihe Rao; David I Stuart
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.